Table 2.
Censoring Reasons and Duration of Follow-up for the Primary Prevention Cohorts After Propensity Score Matching
| Low-intensity statin therapy | ||
| Pravastatin 20–40 mg | Simvastatin 10–20 mg | |
| N= 9,703 | N= 9,703 | |
| Censoring reasons, n (%) | ||
| Muscular event (outcome) | 82 (0.8) | 98 (1.0) |
| Recording of statin intolerance | 17 (0.2) | 47 (0.5) |
| Treatment switch | 1,287 (13.3) | 716 (7.4) |
| Discontinuation of statin treatment | 1,758 (18.1) | 1,802 (18.6) |
| Death | 40 (0.4) | 26 (0.3) |
| Recording of an exclusion criterion | 198 (2.0) | 175 (1.8) |
| Myocardial infarction or ischemic stroke | 283 (2.9) | 206 (2.1) |
| End of study enrollment | 6,038 (62.2) | 6,633 (68.4) |
| Duration of follow-up | ||
| Mean number of days (standard deviation) | 285.0 (112.5) | 295.4 (109.1) |
| Median number of days (interquartile range) | 365 (183–365) | 365 (212–365) |
| Moderate- to high-intensity statin therapy | ||
| Rosuvastatin 5–40 mg | Atorvastatin 10–80 mg | |
| N= 7,032 | N= 7,032 | |
| Censoring reasons, n (%) | ||
| Muscular event (outcome) | 100 (1.4) | 86 (1.2) |
| Recording of statin intolerance | 20 (0.3) | 22 (0.3) |
| Treatment switch | 678 (9.6) | 661 (9.4) |
| Discontinuation of statin treatment | 1,408 (20.0) | 1,378 (19.6) |
| Death | 8 (0.1) | 15 (0.2) |
| Recording of an exclusion criterion | 126 (1.8) | 135 (1.9) |
| Myocardial infarction or ischemic stroke | 59 (0.8) | 81 (1.2) |
| End of study enrollment | 4,633 (65.9) | 4,654 (66.2) |
| Duration of follow-up | ||
| Mean number of days (standard deviation) | 292.1 (110.5) | 293.7 (108.3) |
| Median number of days (interquartile range) | 365 (205–365) | 365 (208–365) |
| Simvastatin 40–80 mg | Atorvastatin 10–20 mg | |
| N= 37,743 | N= 37,743 | |
| Censoring reasons, n (%) | ||
| Muscular event (outcome) | 483 (1.3) | 368 (1.0) |
| Recording of statin intolerance | 214 (0.6) | 166 (0.4) |
| Treatment switch | 3,529 (9.4) | 3,156 (8.4) |
| Discontinuation of statin treatment | 7,279 (19.3) | 7,526 (19.9) |
| Death | 110 (0.3) | 91 (0.2) |
| Recording of an exclusion criterion | 686 (1.8) | 651 (1.7) |
| Myocardial infarction or ischemic stroke | 713 (1.9) | 467 (1.2) |
| End of study enrollment | 24,729 (65.5) | 25,318 (67.1) |
| Duration of follow-up | ||
| Mean number of days (standard deviation) | 282.6 (115.4) | 287.3 (110.8) |
| Median number of days (interquartile range) | 365 (176–365) | 365 (188–365) |